

WHAT IS CLAIMED IS:

1. An isolated nucleic acid encoding a polypeptide comprising at least one of the biological activities of Osteoprotegerin wherein the nucleic acid is selected from the group consisting of:
 - a) the nucleic acids shown in Figures 2B (SEQ ID NO: ____), 9A (SEQ ID NO: ____), and 9B (SEQ ID NO: ____) or complementary strands thereof;
 - b) nucleic acids which hybridize under stringent conditions with the polypeptide-encoding regions as shown in Figures 2B (SEQ ID NO: ____), 9A (SEQ ID NO: ____) and 9B (SEQ ID NO: ____);
 - c) nucleic acids which hybridize under stringent conditions with nucleotides 148 through 337 inclusive as shown in Figure 2B; and
 - d) nucleic acid which are degenerate to the nucleic acids of (a), (b) and (c).
2. The nucleic acid of Claim 1 which is cDNA, genomic DNA, synthetic DNA or RNA.
3. A polypeptide encoded by the nucleic acid of Claim 1.
4. The nucleic acid of Claim 1 including one or more codons preferred for Escherichia coli expression.
5. The nucleic acid of Claim 1 having a detectable label attached thereto.
6. The nucleic acid of Claim 1 comprising the polypeptide-encoding region of Figure 2B (SEQ ID NO: ____), Figure 9A (SEQ ID NO: ____) or Figure 9B (SEQ ID NO: ____).

7. The nucleic acid of Claim 6 having the sequence as shown in Figure 9B from nucleotides 158-1297.

5 8. An expression vector comprising the nucleic acid of Claim 1.

10 9. The expression vector of Claim 8 wherein the nucleic acid comprises the polypeptide - encoding region as shown in Figure 9B (SEQ ID NO: ____).

10. A host cell transformed or transfected with the expression vector of Claim 8.

15 11. The host cell of Claim 10 which is a eucaryotic cell.

20 12. The host cell of Claim 11 which is selected from the group consisting of CHO, COS, 293, 3T3, CV-1 and BHK cells.

13. The host cell of Claim 10 which is a procaryotic cell.

25 14. The host cell of Claim 13 which is Escherichia coli.

15. A transgenic mammal comprising the expression vector of Claim 8.

30 16. The transgenic mammal of Claim 15 which is a rodent.

35 17. The transgenic mammal of Claim 16 which is a mouse.

18. A process for the production of
Osteoprotegerin comprising:

growing under suitable nutrient conditions
host cells transformed or transfected with the nucleic
5 acid of Claim 1; and

isolating the polypeptide products of the
expression of the nucleic acids.

19. A purified and isolated polypeptide comprising
10 Osteoprotegerin.

20. The polypeptide of Claim 19 which is mammalian
Osteoprotegerin.

15 21. The polypeptide of Claim 20 which is human
Osteoprotegerin.

22. The polypeptide of Claim 19 which is
substantially free of other human proteins.

20 23. The polypeptide of Claim 21 having the amino
acid sequence as shown in Figure 2B (SEQ ID NO: ____),
Figure 9A (SEQ ID NO: ____), or Figure 9B (SEQ ID NO:
____) or a derivative thereof.

25 24. The polypeptide of Claim 23 having the amino
acid sequence as shown in Figure 9B from residues 22-
401 inclusive.

30 25. The polypeptide of Claim 23 having the amino
acid sequence as shown in Figure 9B (SEQ ID NO: ____)
from residues 32-401 inclusive.

35 26. The polypeptide of Claim 19 which is
characterized by being a product of expression of an
exogenous DNA sequence.

27. The polypeptide of Claim 26 wherein the DNA is cDNA, genomic DNA or synthetic DNA.

5 28. The polypeptide of Claim 19 which has been modified with a water-soluble polymer.

29. The polypeptide of Claim 28 wherein the water soluble polymer is polyethylene glycol.

10 30. An antibody or fragment thereof which specifically binds to Osteoprotegerin.

15 31. The antibody of Claim 30 which is a monoclonal antibody.

32. A method for detecting the presence of Osteoprotegerin in a biological sample comprising:
incubating the sample with the antibody of
20 Claim 30 under conditions that allow binding of the antibody to osteoprotegerin; and
detecting the bound antibody.

33. A method to assess the ability of a candidate substance to bind to Osteoprotegerin comprising:
incubating Osteoprotegerin with the candidate substance under conditions that allow binding; and
measuring the bound substance.

30 34. A method of regulating the levels of osteoprotegerin in an animal comprising modifying the animal with a nucleic acid encoding Osteoprotegerin.

35 35. The method of Claim 34 wherein the nucleic acid promotes an increase in the tissue level of Osteoprotegerin.

36. The method of Claim 35 wherein the animal is a human.

5 37. A pharmaceutical composition comprising a therapeutically effective amount of osteoprotegerin in a pharmaceutically acceptable carrier, adjuvant, solubilizer, stabilizer and/or anti-oxidant.

10 38. The composition of Claim 37 wherein the Osteoprotegerin is human Osteoprotegerin.

15 39. The composition of Claim 38 wherein the Osteoprotegerin has the amino acid sequence as shown in Figure 9B.

40. A method of treating a bone disorder comprising administering a therapeutically effective amount of the polypeptide of Claim 19.

20

41. The method of Claim 40 wherein the polypeptide is human Osteoprotegerin.

25 42. The method of Claim 40 wherein the bone disorder is excessive bone loss.

30 43. The method of Claim 42. wherein the bone disorder is selected from the group consisting of osteoporosis, Paget's disease of bone, hypercalcemia, hyperparathyroidism, steroid-induced osteopenia, bone loss due to rheumatoid arthritis, bone loss due to osteomyelitis, osteolytic metastasis, and peridontal bone loss.

35 44. The method of Claim 38 further comprising administering a therapeutically effective amount of a

substances selected from the group consisting of bone morphogenic proteins BMP-1 through BMP-12, TGF- β family members, IL-1 inhibitors, TNF α inhibitors, parathyroid hormone and analogs thereof, parathyroid hormone related protein and analogs thereof, E series prostaglandins, bisphosphonates, and bone-enhancing minerals.